Brokerages forecast that OptimizeRx Co. (NASDAQ:OPRX – Get Rating) will post $0.02 earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for OptimizeRx’s earnings, with estimates ranging from ($0.01) to $0.05. OptimizeRx reported earnings per share of $0.03 during the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that OptimizeRx will report full year earnings of $0.73 per share for the current year, with EPS estimates ranging from $0.63 to $0.83. For the next fiscal year, analysts forecast that the company will post earnings of $1.50 per share, with EPS estimates ranging from $1.24 to $1.75. Zacks’ EPS averages are an average based on a survey of sell-side research firms that that provide coverage for OptimizeRx.
OptimizeRx (NASDAQ:OPRX – Get Rating) last posted its quarterly earnings results on Thursday, February 24th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.06). OptimizeRx had a return on equity of 0.72% and a net margin of 2.70%. The firm had revenue of $20.30 million for the quarter, compared to the consensus estimate of $20.09 million. During the same period in the previous year, the company posted $0.11 EPS.
In related news, CEO William J. Febbo sold 16,666 shares of the stock in a transaction on Friday, February 18th. The stock was sold at an average price of $43.73, for a total transaction of $728,804.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.50% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of OptimizeRx by 140.7% during the 4th quarter. BlackRock Inc. now owns 2,668,088 shares of the company’s stock worth $165,716,000 after purchasing an additional 1,559,669 shares in the last quarter. State Street Corp raised its holdings in shares of OptimizeRx by 88.8% in the fourth quarter. State Street Corp now owns 594,454 shares of the company’s stock worth $36,922,000 after acquiring an additional 279,640 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of OptimizeRx in the third quarter valued at $50,371,000. Handelsbanken Fonder AB lifted its position in shares of OptimizeRx by 9.7% in the fourth quarter. Handelsbanken Fonder AB now owns 560,000 shares of the company’s stock valued at $34,782,000 after acquiring an additional 49,500 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of OptimizeRx by 11.3% during the fourth quarter. American Century Companies Inc. now owns 425,045 shares of the company’s stock valued at $26,399,000 after acquiring an additional 43,131 shares during the last quarter. Institutional investors and hedge funds own 86.10% of the company’s stock.
NASDAQ:OPRX opened at $38.44 on Wednesday. The stock has a market capitalization of $687.12 million, a price-to-earnings ratio of 427.16 and a beta of 0.73. The firm has a 50 day moving average of $40.94 and a 200 day moving average of $57.89. OptimizeRx has a 52 week low of $34.31 and a 52 week high of $99.18.
OptimizeRx Company Profile (Get Rating)
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages.
- Get a free copy of the StockNews.com research report on OptimizeRx (OPRX)
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
- Constellation Brands Stock is Launching Towards New Highs
- 3 Analyst Favorite Blue-Chip Stocks to Buy Now
- Does PNC Financial Stock Belong in Your Portfolio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.